Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELRiSE MDS: Elritercept vs Epoetin Alfa in MDS Anemia
NCT07422480Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 28
01
Overview
A Phase 3 trial of elritercept in anemia, sponsored by Takeda. Started May 2026; status: recruiting.
02
Drugs
elritercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07422480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422480.